Daniel L. Abravanel

Oct 30, 2024 | nature.com | Johanna Klughammer |Daniel L. Abravanel |Timothy R. Blosser |Yury Goltsev |Chiara Caraccio |Nicole Cullen | +7 more

AbstractAlthough metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. In this study, we assembled a multi-modal spatial and cellular map of 67 tumor biopsies from 60 patients with metastatic breast cancer across diverse clinicopathological features and nine anatomic sites with detailed clinical annotations.

Mar 19, 2024 | nature.com | Ann H. Partridge |Beth Overmoyer |Nabihah Tayob |Sara M. Tolaney |Qingchun Jin |Alyssa Pereslete | +1 more

AbstractThe landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer.